Status
Conditions
Treatments
About
Patient derived xenografts (PDX) from mammary tumors are usually made from metastatic tumors. Indeed, PDX from primitive mammary tumors or after neoadjuvant treatment are still rare. However, the realization of such PDX (from primitive mammary tumors or after neoadjuvant treatment) would make it possible to have a better knowledge of the tumor heterogeneity to the therapeutic response, to explore the models of tumor evolution during metastatic progression and also observe the mechanisms of tumor resistance in the case of non-metastatic tumors. It therefore seems necessary to develop PDX from primitive tumors in order to observe firstly the success rate of PDX; on the other hand, the drift of the initial heterogeneity, measured by comparison of the histomolecular profile of the tumors with that of the PDXs. It aims to develop xenografts from tumor samples from surgical specimens of patients with triple negative or luminal B breast cancer.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2
Signature of the participation consent to the study,
Affiliation to a social security scheme
Major woman with:
Patients in a metastatic situation can be included regardless of the therapeutic line.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
85 participants in 1 patient group
Loading...
Central trial contact
Judith PASSILDAS, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal